Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018743 | 0.82 | MAPT (0.51) | GPR35ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL1525403 | 0.81 | CES2 (0.57) | ALDH1A1SMN1; SMN2GAATDP1MAPT | |
| SCHEMBL21061040 | 0.80 | ABCB1 (0.44) | ABCB1TPMTGPR35ALDH1A1SMN1; SMN2 | |
| SCHEMBL2662880 | 0.80 | CA12 (0.62) | TPMTL3MBTL1CA12CA1CA2 | |
| SCHEMBL27611205 | 0.80 | MAPT (0.58) | GPR35ALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL4578196 | 0.77 | ESR1 (0.53) | ALDH1A1SMN1; SMN2TDP1MAPTL3MBTL1 | |
| SCHEMBL2529911 | 0.77 | CES2 (0.56) | ALDH1A1SMN1; SMN2GAATDP1MAPT | |
| SCHEMBL5514458 | 0.77 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2GAAHTT | |
| SCHEMBL2643972 | 0.77 | TSHR (0.50) | ALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL11836859 | 0.77 | CES2 (0.52) | ALDH1A1SMN1; SMN2GAATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392138-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200392138-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| CN-111511721-A | Pesticidally active mesoionic heterocyclic compounds | 先正达参股股份有限公司 | 2020-08-07 | — | — | CN | disclosed |
| WO-2019115404-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115404-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-06-20 | — | — | WO | disclosed |
| EP-2440553-B1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8470773-B2 | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120108505-A1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION | 2012-05-03 | — | — | US | disclosed |
| EP-2440553-A1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | Schering Corporation (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144664-A1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108505-A1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GPR119 | ABCB1 1057/4885TPMT 515/4885GPR35 152/4885 |
| US-20200392138-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | DDT, ACHE, MNS1 | ABCB1 2096/4885TPMT 1227/4885GPR35 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.